NCT00056862View on ClinicalTrials.gov

Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3

PHASE4CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

January 31, 2010

Study Completion Date

June 30, 2010

Conditions
Hepatitis C
Interventions
DRUG

Peginterferon alfa-2a

Peginterferon alfa-2a 90 mcg/week

DRUG

Peginterferon alfa-2a

180 mcg/week

DRUG

Ribavirin

800 mg/day

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

NCT00056862 - Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3 | Biotech Hunter | Biotech Hunter